KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Sabra Health Care REIT (SBRA) Shares Outstanding (Weighted Average) (2016 - 2022)

Sabra Health Care REIT has reported Shares Outstanding (Weighted Average) over the past 13 years, most recently at $230.9 million for Q1 2022.

  • For Q1 2022, Shares Outstanding (Weighted Average) rose 9.18% year-over-year to $230.9 million; the TTM value through Mar 2022 reached $230.9 million, up 9.18%, while the annual FY2021 figure was $219.1 million, 6.23% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2022 was $230.9 million at Sabra Health Care REIT, up from $219.1 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $230.9 million in Q1 2022 and troughed at $178.3 million in Q1 2018.
  • A 5-year average of $198.5 million and a median of $205.4 million in 2020 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 172.81% in 2018 and later rose 0.05% in 2019.
  • Year by year, Shares Outstanding (Weighted Average) stood at $178.3 million in 2018, then increased by 2.96% to $183.6 million in 2019, then increased by 12.34% to $206.2 million in 2020, then rose by 6.23% to $219.1 million in 2021, then grew by 5.38% to $230.9 million in 2022.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SBRA at $230.9 million in Q1 2022, $219.1 million in Q4 2021, and $220.9 million in Q3 2021.